Loading
PT
Pandion Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Becker Daniel J., was filed 23 Nov 2020.
Pandion Therapeutics, Inc.: what insiders have been doing
Pandion Therapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Pandion Therapeutics, Inc. The previous disclosure was published on 1 April 2021.
The full history, which starts in 2020, counts 19 purchases against no sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
77
Thresholds
n/a
Buy Volume
€22M
19 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
Revenue7.8M
Net income-33.9M-434.0% margin
Last declaration on 1 April 2021
Declarations77 total
87,764 shares@ US$60.0099.5% of flowCommon StockSEC:0000899243-21-014466:0
54,460 shares@ US$60.00100.0% of flowCommon StockSEC:0000899243-21-014459:0
1,000 shares@ US$60.001.3% of flowCommon StockSEC:0000899243-21-014447:0
115,826 shares@ US$60.0099.5% of flowCommon StockSEC:0000899243-21-014448:0
13,196 shares@ US$60.00100.0% of flowCommon StockSEC:0000899243-21-014456:0
14,000 shares@ US$60.001.9% of flowCommon StockSEC:0000899243-21-014453:0
702,515 shares@ US$60.0097.5% of flowCommon StockSEC:0000899243-21-014453:1
503,254 shares@ US$60.0099.7% of flowCommon StockSEC:0000899243-21-014467:0
1,200 shares@ US$60.000.2% of flowCommon StockSEC:0000899243-21-014467:1
84,158 shares@ US$60.002.3% of flowCommon StockSEC:0000899243-21-014462:0
22,125 shares@ US$60.0099.2% of flowCommon StockSEC:0000899243-21-014435:0
61,113 shares@ US$60.0095.2% of flowCommon StockSEC:0000899243-21-014443:0
5,674,221 shares@ US$60.0098.1% of flowCommon StockSEC:0000899243-21-014441:0
2,107,513 shares@ US$60.0098.9% of flowCommon StockSEC:0000899243-21-014452:0
23,622 shares@ US$60.001.1% of flowCommon StockSEC:0000899243-21-014452:1
1,000 shares@ US$60.000.0% of flowCommon StockSEC:0000899243-21-014451:0
2,827,883 shares@ US$60.0098.0% of flowCommon StockSEC:0000899243-21-014451:1
73,067 shares@ US$60.0098.2% of flowCommon StockSEC:0000899243-21-014447:1
336,314 shares@ US$60.009.2% of flowCommon StockSEC:0000899243-21-014462:1
3,090,801 shares@ US$60.0085.0% of flowCommon StockSEC:0000899243-21-014462:2
110,621 shares@ US$60.003.0% of flowCommon StockSEC:0000899243-21-014462:3
197,716 shares@ US$15.1217.8% of flowCommon StockSEC:0000899243-20-031941:0
Canonical exit: 17 Feb 2021 (T+90)
2,170 shares@ US$14.630.2% of flowCommon StockSEC:0000899243-20-031744:0
Canonical exit: 15 Feb 2021 (T+90)
13,027 shares@ US$15.431.2% of flowCommon StockSEC:0000899243-20-031744:1
Canonical exit: 15 Feb 2021 (T+90)
14,197 shares@ US$15.261.3% of flowCommon StockSEC:0000899243-20-031744:2
Canonical exit: 16 Feb 2021 (T+90)
25 of 77 declarations
About Pandion Therapeutics, Inc.
Pandion Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases. It utilizes a drug design platform to create targeted treatments.
